Erratum: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176))

G. V. Long; K. T. Flaherty; D. Stroyakovskiy; H. Gogas; E. Levchenko; F. de Braud; J. Larkin; C. Garbe; T. Jouary; A. Hauschild; V. Chiarion-Sileni; C. Lebbe; M. Mandalá; M. Millward; A. Arance; I. Bondarenko; J. B.A.G. Haanen; J. Hansson; J. Utikal; V. Ferraresi; P. Mohr; V. Probachai; D. Schadendorf; P. Nathan; C. Robert; A. Ribas; M. A. Davies; S. R. Lane; J. J. Legos; B. Mookerjee; J. J. Grob

doi:10.1093/annonc/mdz221

Erratum: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176))

G. V. Long, K. T. Flaherty, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, V. Chiarion-Sileni, C. Lebbe, M. Mandalá, M. Millward, A. Arance, I. Bondarenko, J. B.A.G. Haanen, J. Hansson, J. Utikal, V. FerraresiP. Mohr, V. Probachai, D. Schadendorf, P. Nathan, C. Robert, A. Ribas, M. A. Davies, S. R. Lane, J. J. Legos, B. Mookerjee, J. J. Grob

Résultats de recherche: Contribution à un journal › !!Comment/debate

27 Citations (Scopus)

Résumé

Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176) The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”

langue originale	Anglais
Pages (de - à)	1848
Nombre de pages	1
journal	Annals of Oncology
Volume	30
Numéro de publication	11
Les DOIs	https://doi.org/10.1093/annonc/mdz221
état	Publié - 1 nov. 2019

Accès au document

10.1093/annonc/mdz221

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., ... Grob, J. J. (2019). Erratum: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176)). Annals of Oncology, 30(11), 1848. https://doi.org/10.1093/annonc/mdz221

Long, G. V. ; Flaherty, K. T. ; Stroyakovskiy, D. et al. / Erratum : Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176)). Dans: Annals of Oncology. 2019 ; Vol 30, Numéro 11. p. 1848.

@article{d999f39f7d4f4c7db48bbe5c9c285126,

title = "Erratum: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176))",

abstract = "Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176) The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”",

author = "Long, {G. V.} and Flaherty, {K. T.} and D. Stroyakovskiy and H. Gogas and E. Levchenko and {de Braud}, F. and J. Larkin and C. Garbe and T. Jouary and A. Hauschild and V. Chiarion-Sileni and C. Lebbe and M. Mandal{\'a} and M. Millward and A. Arance and I. Bondarenko and Haanen, {J. B.A.G.} and J. Hansson and J. Utikal and V. Ferraresi and P. Mohr and V. Probachai and D. Schadendorf and P. Nathan and C. Robert and A. Ribas and Davies, {M. A.} and Lane, {S. R.} and Legos, {J. J.} and B. Mookerjee and Grob, {J. J.}",

note = "Publisher Copyright: {\textcopyright} 2019 THE AUTHORS",

year = "2019",

month = nov,

day = "1",

doi = "10.1093/annonc/mdz221",

language = "English",

volume = "30",

pages = "1848",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "11",

}

Long, GV, Flaherty, KT, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, JBAG, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, MA, Lane, SR, Legos, JJ, Mookerjee, B & Grob, JJ 2019, 'Erratum: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176))', Annals of Oncology, VOL. 30, Numéro 11, p. 1848. https://doi.org/10.1093/annonc/mdz221

Erratum: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176)). / Long, G. V.; Flaherty, K. T.; Stroyakovskiy, D. et al.
Dans: Annals of Oncology, Vol 30, Numéro 11, 01.11.2019, p. 1848.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Erratum

T2 - Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176))

AU - Long, G. V.

AU - Flaherty, K. T.

AU - Stroyakovskiy, D.

AU - Gogas, H.

AU - Levchenko, E.

AU - de Braud, F.

AU - Larkin, J.

AU - Garbe, C.

AU - Jouary, T.

AU - Hauschild, A.

AU - Chiarion-Sileni, V.

AU - Lebbe, C.

AU - Mandalá, M.

AU - Millward, M.

AU - Arance, A.

AU - Bondarenko, I.

AU - Haanen, J. B.A.G.

AU - Hansson, J.

AU - Utikal, J.

AU - Ferraresi, V.

AU - Mohr, P.

AU - Probachai, V.

AU - Schadendorf, D.

AU - Nathan, P.

AU - Robert, C.

AU - Ribas, A.

AU - Davies, M. A.

AU - Lane, S. R.

AU - Legos, J. J.

AU - Mookerjee, B.

AU - Grob, J. J.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176) The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”

AB - Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176) The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”

UR - http://www.scopus.com/inward/record.url?scp=85077175829&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz221

DO - 10.1093/annonc/mdz221

M3 - Comment/debate

C2 - 31406976

AN - SCOPUS:85077175829

SN - 0923-7534

VL - 30

SP - 1848

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F et al. Erratum: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Annals of Oncology (2017) 28(7) (1631–1639), (S0923753419322707), (10.1093/annonc/mdx176)). Annals of Oncology. 2019 nov. 1;30(11):1848. doi: 10.1093/annonc/mdz221